IMCR — Immunocore Holdings Income Statement
0.000.00%
Last trade - 00:00- $1.86bn
- $1.36bn
- $310.20m
- 62
- 17
- 65
- 45
Annual income statement for Immunocore Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 10-K | 10-K | 10-K | 10-K |
| Standards: | IFRS | USG | USG | USG | USG |
| Status: | fx Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 38.6 | 36.5 | 174 | 249 | 310 |
| Cost of Revenue | |||||
| Gross Profit | — | 36.5 | 173 | 248 | 307 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 149 | 211 | 228 | 309 | 381 |
| Operating Profit | -111 | -175 | -53.4 | -59.6 | -70.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -112 | -180 | -40.9 | -60.9 | -52.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -95 | -180 | -52.5 | -55.3 | -51.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -95 | -180 | -52.5 | -55.3 | -51.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -95 | -180 | -52.5 | -55.3 | -51.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.32 | -4.24 | -1.13 | -1.13 | -1.02 |